A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Takeda

Status and phase: Completed; Phase 3

Conditions: Parkinson's Disease

Treatments: Drug: TVP-1012 1mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT02337764

JapicCTI-152762 (Registry Identifier)

TVP-1012/OCT-002

U1111-1165-1500 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.

Full description

This is a multicenter, open-label, long-term, phase 3 study to evaluate the safety and efficacy of long-term administration of TVP-1012 at 1 mg with levodopa in Japanese participants with Parkinson's disease.

The study period consisted of a 2-week run-in period and a subsequent 52-week treatment period. Participants fulfilling the inclusion criteria and did not meet any of the exclusion criteria at the start of the run-in period (Week -2) and also at the end of the run-in period (Week 0) were enrolled in the study, and received 1 mg of TVP-1012 once daily for 52 weeks, in an unblinded manner, from the day after Week 0.

Enrollment: 222 patients

Sex: All

Ages: 30 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.

• The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

• The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.

• The participant has received a levodopa combination drug for >= 1 month at the start of the run-in period and has either of the following.

  • Wearing off phenomenon
  • Decreased response to levodopa combination drugs

• The participant has been receiving a levodopa combination drug a stable dose regimen since the start of the run-in period.

• The participant is an outpatient of either sex aged >= 30 and < 80 years at the time of consent.

• A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.

Exclusion criteria

• The participant has received any investigational medication within 90 days prior to the start of the run-in period.

• The participant has received TVP-1012 in the past.

• The participant is a study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.

• Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.

• The participant has Modified Hoehn & Yahr stage 5 (or stage 5 at eather on-time or off-time for the participant with wearing off phenomenon) at the start of the run-in period.

• The participant has severe dyskinesia.

• The participant has unstable systemic disease.

• The participant has a Mini-Mental State Examinations (MMSE) score of <= 24 at the start of the run-in period..

• The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease.

• The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.

• The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).

• The participant has a history or concurrent of drug abuse or alcohol dependence.

• The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).

• The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period.

• The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.

• The participant has received single agent of levodopa, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days prior to the start of the run-in period may be included in the study.

• The participant is required to take any of the prohibited concomitant medications or treatments.

• If female, the participant is pregnant or lactating or intending to become pregnant during, or within 1 month after the last administration of study medication in this study; or intending to donate ova during such time period.

• The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.

• The participant has clinically significant or unstable brain or cardiovascular disease, such as:

  • clinically significant arrhythmia or cardiac valvulopathy,
  • heart failure of NYHA Class II or higher,
  • concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,
  • concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the stat of the run-in period,
  • severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),
  • clinically significant orthostatic hypotension (including those with diastolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position), or
  • a history of syncope due to hypotension within 2 years prior to the stat of the run-in period.

• The participant is required surgery or hospitalization for surgery during the study period.

• Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.

• The participant has acquired immunodeficiency syndrome (AIDS) [including human immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.

• The participant with laboratory data meeting any of the following at the start of the run-in period:

  • Creatinine >= 2 x upper limit of normal (ULN)
  • Total bilirubin >= 2 x ULN
  • ALT or AST >= 1.5 x ULN
  • ALP >= 3 x ULN

• The participant has received any of the prohibited concomitant medications or treatments during the run-in period

• The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

222 participants in 1 patient group

TVP-1012 1mg

Experimental group

Description:

TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.

Treatment:

Drug: TVP-1012 1mg